Neuropilin-1 is a member of the neuropilins family protein, which contains a large extracellular domain (a1a2, b1b2 and c), a single transmembrane domain, and a short cytoplasmic tail. NRP-1 plays a critical role in angiogenesis and stimulates endothelial cell division and migration by binding VEGF165 with b1b2 domain. In the present study, we report the establishment of a monoclonal antibody (A6-26-11-26 clone) specific for NRP-1 b1b2 through hybridoma method. Western blot analysis indicates that our NRP-1 b1b2 MAb can combine both NRP-1 b1b2 and NRP-1 originated from tumor cells. This monoclonal antibody against NRP-1 b1b2 will be useful in the further development of cancer target strategy.
Get full access to this article
View all access options for this article.
References
1.
HeZ, Tessier-LavigneM. Neuropilin is a receptor for the axonal chemorepellent Semaphorin III. Cell, 1997; 90:739–751.
2.
SokerS, TakashimaS, MiaoHQ, NeufeldG, KlagsbrunM. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell, 1998; 92:735–745.
3.
KlagsbrunM, TakashimaS, MamlukR. The role of neuropilin in vascular and tumor biology. Adv Exp Med Biol, 2002; 515:33–48.
4.
BeckmannG, BorkP. An adhesive domain detected in functionally diverse receptors. Trends Biochem Sci, 1993; 18:40–41.
5.
Vander KooiCW, JusinoMA, PermanB, NeauDB, BellamyHD, LeahyDJ. Structural basis for ligand and heparin binding to neuropilin B domains. Proc Natl Acad Sci USA, 2007; 104:6152–6157.
6.
WhitakerGB, LimbergBJ, RosenbaumJS. Vascular endothelial growth receptor-2 and neuropilin-1 form a receptor complex that is responsible for the differential signaling potency of VEGF165 and VEGF121. J Biol Chem, 2001; 276:25520–25531.
7.
KohlerG, MilsteinC. Derivation of specific antibody producing tissue culture and tumor lines by cell fusion. Eur J Immunol, 1976; 6:511–519.
8.
KimKJ, AlphonsoM, SchmelzerCH, LoweD. Detection of human leukemia inhibitory factor by monoclonal antibody based ELISA. J Immunol Method, 1992; 156,1:9–17.
9.
EyPL, ProwseSJ, JenkinCR. Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose. Immunochemistry, 1978; 15:429–436.
10.
HerzogY, KalcheimC, KahaneN, ReshefR, NeufeldG. Differential expression of neuropilin-1 and neuropilin-2 in arteries and veins. Mech Dev, 2001; 109:115–119.
11.
YuanL, MoyonD, PardanaudL, BreantC, KarkkainenMJ, AlitaloK, EichmannA. Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development, 2002; 129:4797–4806.
12.
SokerS, TakashimaS, MiaoHQ, NeufeldG, KlagsbrunM. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell, 1998; 92:735–745.
13.
GuC, RodriguezER, ReimertDV, ShuT, FritzschB, RichardsLJ, KolodkinAL, GintyDD. Neuropilin-1 conveys semaphoring and VEGF signaling during neural and cardiovascular development. Dev Cell, 2003; 5:45–57.
14.
KerbelRS, YuJ, TranJ, ManS, Viloria-PetitA, KlementG, CoomberBL, RakJ. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev, 2001; 20:79–86.
15.
JainRK, DudaDG, ClarkJW, LoefflerJS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol, 2006; 3:24–40.
